MicroRNA expression profiles associated with acquired gefitinib‑resistance in human lung adenocarcinoma cells

Ge,Xiaojun; Zheng,Limei; Huang,Min; Wang,Yonglun; Bi,Feng

doi:10.3892/mmr.2014.2757

MicroRNA expression profiles associated with acquired gefitinib‑resistance in human lung adenocarcinoma cells

Authors:
- Xiaojun Ge
- Limei Zheng
- Min Huang
- Yonglun Wang
- Feng Bi
View Affiliations

Affiliations: Department of Medical Oncology and Laboratory of Signal Transduction and Molecular Targeted Therapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Laboratory Medicine, Affiliated Hospital of Zun Yi Medical College, Zun Yi, Guizhou 563003, P.R. China, Department of Occupational and Environmental Health, School of Public Health, Ningxia Medical University, Ningxia 750004, P.R. China
Published online on: October 23, 2014 https://doi.org/10.3892/mmr.2014.2757
Pages: 333-340

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to establish, characterize and elucidate the potential mechanisms of acquired gefitinb resistance, using the A549 human lung cancer cell line. A gefitinib‑resistant A549 sub‑clone was established by exposure to escalating gefitinib concentrations over a period of 16‑24 months. Half maximal inhibitory concentration (IC50) values were quantified using a real time cytotoxicity assay. The expression profiles of the parent and resistant sub‑clone A549 cells were detected using the µParaflo® Microfluidics Biochip microRNA (miRNA) Microarray. The ArrayPro software was used to analyze the differential expression levels of the miRNA, and bioinformatics software was used to predict the potential target genes of the differentially expressed miRNAs. Quantitative polymerase chain reaction (qPCR) was used to confirm the results of the miRNA microarray. A miRNA mimic was transfected into the gefitinib‑resistant cells, in order to predict target gene interaction effects, following gefitinib treatment. Protein expression level differences were confirmed by western‑blot analysis. Real time cytotoxicity assays revealed a 3‑fold increase in the IC50 values of the gefitinib‑resistant sub‑clones, as compared with the parent cells. There were marked morphological differences between the parent and resistant cells. In the microarray analysis, the gefitinib‑resistant sub‑clones had 25 upregulated and 18 downregulated miRNAs, as compared with the parent cells. The qPCR revealed that miR‑7 was significantly downregulated, which was concordant with the results of the microarray. The results of the present study suggest that miR‑7 may significantly improve the sensitivity of cancer cells to gefitinib. The data presented in the present study provides an experimental basis and theory that miRNAs may be involved in acquired gefitinib‑resistance of lung adenocarcinoma, and miR‑7 may have potential clinical effects in the reversal of drug resistance.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Mendlsohn J and Baserga J: The EGF receptor family as targets for cancer therapy. Oncogene. 19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
3	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246. 2003.
4	Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003. View Article : Google Scholar
5	Nakagawa K, Tamura T, Negoro S, et al: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumours. Ann Oncol. 14:922–930. 2003.
6	Jackman D, Pao W, Riely GJ, et al: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar
7	Peled N, Wynes MW, Ikeda N, et al: Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr). 36:277–288. 2013. View Article : Google Scholar : PubMed/NCBI
8	Roybal JD, Zang Y, Ahn YH, et al: miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 9:25–35. 2011. View Article : Google Scholar : PubMed/NCBI
9	Esquela-Kerscher A, Trang P, Wiggins JF, et al: The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 7:759–764. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ambros V: microRNAs: tiny regulators with great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
11	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
12	Leung AK and Sharp PA: microRNAs: a safeguard against turmoil? Cell. 130:581–585. 2007. View Article : Google Scholar : PubMed/NCBI
13	Coldren CD, Helfrich BA, Witta SE, et al: Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 4:521–528. 2006. View Article : Google Scholar : PubMed/NCBI
14	Uphoff CC and Drexler HG: Detecting mycoplasma contamination in cell cultures by polymerase chain reaction. Methods Mol Biol. 731:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
15	Gainor JF and Shaw AT: Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 31:3987–3996. 2013. View Article : Google Scholar : PubMed/NCBI
16	Guo L, Liu Y, Bai Y, Sun Y, Xiao F and Guo Y: Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer. 46:1692–1702. 2010. View Article : Google Scholar : PubMed/NCBI
17	Nguemo F, Šarić T, Pfannkuche K, Watzele M, Reppel M and Hescheler J: In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cell Physiol Biochem. 29:819–832. 2012. View Article : Google Scholar : PubMed/NCBI
18	Rho JK, Choi YJ, Lee JK, et al: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. 63:219–226. 2009. View Article : Google Scholar : PubMed/NCBI
19	Maftouh M, Avan A, Galvani E, Peters GJ and Giovannetti E: Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer. Crit Rev Oncog. 18:317–326. 2013. View Article : Google Scholar
20	Kitamura K, Seike M, Okano T, et al: MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther. 13:44–453. 2014.PubMed/NCBI
21	Dong Z, Zhong Z, Yang L, Wang S and Gong Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
22	An IS, An S, Kwon KJ, Kim YJ and Bae S: Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells. Oncol Rep. 29:523–528. 2013.PubMed/NCBI
23	Garofalo M, Romano G, Di Leva G, et al: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 18:74–82. 2011.
24	Kefas B, Godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
25	Giles KM, Barker A, Zhang PM, Epis MR and Leedman PJ: MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol. 676:147–163. 2011. View Article : Google Scholar : PubMed/NCBI
26	Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS and Leedman PJ: Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 284:5731–5741. 2009. View Article : Google Scholar : PubMed/NCBI
27	Li X and Carthew RW: A microRNA mediates EGF receptor signaling and promotes photorecepotor differentiation in the Drosophila eye. Cell. 123:1267–1277. 2005. View Article : Google Scholar : PubMed/NCBI
28	Jiang L, Liu X, Chen Z, et al: MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J. 432:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
29	Stark A, Brennecke J, Russell RB and Cohen SM: Identification of Drosophila microRNA targets. PLoS Biol. 1:E602003. View Article : Google Scholar : PubMed/NCBI
30	Reddy SD, Ohshiro K, Rayala SK and Kumar R: MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res. 68:8195–8200. 2008. View Article : Google Scholar : PubMed/NCBI
31	Masuda M, Miki Y, Hata S, et al: An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. J Transl Med. 10:S22012. View Article : Google Scholar : PubMed/NCBI